Vir's Follow-On Tests Whether Open Equity Windows Favor Platform Stories Over Small-Cap Fixes
Vir Biotechnology's unpriced offering lands the same week as a $225M Windward IPO and a string of warrant-laden small-cap raises, showing how differently capital is available across biotech.
What happened
Vir Biotechnology (Nasdaq: VIR) announced on November 12 a proposed underwritten public offering of common stock. Underwriters get a 30-day option to buy up to 15% additional shares. Leerink Partners, Morgan Stanley and Evercore ISI are bookrunners. Size and pricing have not been set, and completion depends on market conditions.
The announcement gives no figures for proceeds, use of funds or the existing cash position, so we do not speculate on them. What it does confirm is the company's description of its pipeline: chronic hepatitis delta, and PRO-XTEN masked T-cell engagers for solid tumors. Those are two distinct bets with very different development timelines and capital needs.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Vir Biotechnology launches underwritten public offering of common stock Vir Biotechnology, Inc. · 16 Nov 2026
- InspireMD prices $37.5M public offering of stock, pre-funded warrants and warrants to fund CGuard Prime InspireMD, Inc. · 16 Nov 2026
- XORTX Therapeutics files Q3 2026 MD&A; company delisted from TSX Venture Exchange effective Sept 1 XORTX Therapeutics Inc. · 16 Nov 2026
- IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M IM Cannabis Corp. · 13 Nov 2026
- Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597 Femasys Inc · 13 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Tenon Medical's $15.6M raise clears convertibles and Nasdaq risk, but not the funding question
The SI joint fusion maker used a quarter of financing to repay senior notes early and regain listing compliance. Peers' Q3 raises show how different the small-cap capital market has become.
IM Cannabis funds a shrinking business with converts while peers raise on scale and strategics
IM Cannabis's nine-month loss and shareholders' deficit sit against a week of financings in which strategic capital and clinical catalysts, not survival needs, set the terms.
Femasys's $30M placement funds a U.S. launch and a pivotal trial as sales slip 44.5%
Femasys closed a $30M private placement to build a FemaSeed sales team and run the FemBloc pivotal trial. Q3 sales fell 44.5%, and the financing market around it is split between large IPOs and small, structured raises.